Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab: An Umbrella Bayesian Optimal Phase II Study.

NCT05788081 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

NCT NCT05788081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05788081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab: An Umbrella Bayesian Optimal Phase II Study.
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 31, 2023
Completion date
June 1, 2027
Enrollment
40 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma stage ii, follicular lymphoma stage iii, follicular lymphoma stage iv